Valeant Pharmaceuticals Intl Inc news

   Watch this stock
Showing stories 1 - 10 of about 204   

Articles published

VRX 15.50 +1.82 (13.30%)
price chart
Valeant Pharmaceuticals Intl Inc. vs. Jean Coutu Group PJC Inc.: Is the Drug ...
You go to the pharmacy to buy drugs, which are produced by a pharmaceutical company. A pharmacy chain that is well known here in Canada is Jean Coutu Group PJC Inc. (TSX:PJC.A). And regarding pharmaceutical companies, you have certainly heard of ...
Valeant: Was Inova Sale The Worst Deal Ever?  Seeking Alpha
Cantor's First Take: Bullish on Valeant Pharmaceuticals Intl Inc (VRX ...  Smarter Analyst
Is Valeant Pharmaceuticals Intl Inc. a Viable Investment Opportunity?
Most investors have been watching the epic collapse of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) for nearly two years now.
Valeant Pharma nudges higher as billionaire investor joins board  Proactive Investors USA & Canada
Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of ...  Canada NewsWire (press release)
Valeant Pharmaceuticals Intl Inc.: When Is a Good Time to Invest?
Shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) have been on quite the journey over the past few years. It used to be one of the top investments for hedge funds before coming under fire for its pricing of drugs.
Valeant: The Market Wants Growth  Seeking Alpha
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) To Sell Off Its Eye Surgery ...  Journal Transcript
Valeant Pharmaceuticals Intl Inc. Takes Another Step Closer to Death
Last week, shares of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) rose on the news the company was selling a subsidiary business called iNova Pharmaceuticals for approximately $930 million in cash.
Valeant Pharmaceuticals International, Inc. (VRX) Closed at $12.52  HugoPress
Valeant Pharmaceuticals Intl Inc (VRX) Price Target Cut to $15.00  Sports Perspectives
Valeant Announces Sale of iNova Pharmaceuticals for $930 Million
LAVAL, Quebec, June 8, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced it has entered into an agreement to sell its iNova Pharmaceuticals ("iNova") business to a company jointly owned by ...
Valeant Pharmaceuticals Intl Inc. May Raise Another US$2 Billion to Pay Back ...  The Motley Fool Canada
Valeant to sell its iNova Pharmaceuticals business for $1.25B  Financial Post
Contrarian Investors: Don't Expect a Sudden Rebound in Valeant Pharmaceuticals ...
Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in the midst of a transformation overhaul as its new CEO Joseph Papa looks to clean up the mess that Michael Pearson and the old management team left behind.
Valeant Pharmaceuticals Intl Inc (VRX) Risk/Reward Remains Problematic  Smarter Analyst
3 Reasons Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Dangerous to Your ...  Investorplace.com
Bausch + Lomb Named Most Trusted Contact Lens Solution Brand In Canada For ...
LAVAL, Quebec, June 22, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that Bausch + Lomb contact lens solutions ...
Valeant Pharmaceuticals adds prominent US investor John Paulson to board
LAVAL, Que. - Valeant Pharmaceuticals International Inc. (TSX:VRX) says prominent U.S. investor John Paulson has joined its board of directors.
Mizuho Expects Valeant Pharmaceuticals Intl Inc (VRX) Shares to Drift Lower ...  Smarter Analyst
Valeant Pharmaceuticals International, Inc. (VRX) Stock is Risky?  Stocks Gallery
Does Valeant Pharmaceuticals Intl Inc (VRX) Stock Have a Bull Case?
If you are brave enough to buy Valeant Pharmaceutical now, you are buying a stabilized company at one-half its sales, which had a decent profit margin in the first quarter and with a more patient hedge fund billionaire, John Paulson, now on the board.
Valeant Pharmaceuticals International Inc. (VRX:CA) Rises 12.57% for June 22  Equities.com
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Hopes To Obtain About $930M From ...  Journal Transcript
Valeant Pharmaceuticals Intl Inc's (VRX) Bausch + Lomb Named Most Trusted ...
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) wholly owned subsidiary, Bausch + Lomb, a leading global eye health company, today announced that Bausch + Lomb contact lens solutions have been named the most trusted contact lens solution brand for the ...
With Shares Trading up at $13.68 (VRX) Bausch + Lomb Named Most Trusted ...  Highlight Press